Aldeyra Therapeutics grants stock options to director

Aldeyra Therapeutics, Inc. reported that director William D. Clark received two stock option awards as equity compensation.

Rhea-AI Filing Summary

Aldeyra Therapeutics, Inc. reported that director William D. Clark received two stock option awards as equity compensation. One option for 2,323 shares of common stock and another for 70,000 shares were granted with an exercise price of $1.72 per share and an expiration date of June 8, 2036.

Each grant becomes exercisable for 100% of the underlying shares on the one-year anniversary of the grant date. Vesting is conditioned on Clark providing continuous service, respectively, as a member of the Board of Directors and of the Nominating/Corporate Governance Committee through the applicable vesting date.

Insider Trade Summary

Grant/Award: 72,323 shares

Grant/Award 2 txns

Insider Clark William D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	2,323	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 72,323 contracts (Direct)

Footnotes (2)

1. F1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
2. F2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.

Key Figures

Option grant size 1: 2,323 shares Option grant size 2: 70,000 shares Exercise price: $1.72 per share +2 more

5 metrics

Option grant size 1 2,323 shares Stock Option (Right to Buy) granted to director

Option grant size 2 70,000 shares Stock Option (Right to Buy) granted to director

Exercise price $1.72 per share Conversion or exercise price for both option grants

Expiration date June 8, 2036 Option expiration for both grants

Vesting schedule 100% after one year Each grant vests on one-year anniversary of grant date

Key Terms

Stock Option (Right to Buy), grant/award acquisition, derivative, Nominating/Corporate Governance Committee, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

Nominating/Corporate Governance Committee financial

"service as a member of the Nominating/Corporate Governance Committee of the Board"

A nominating/corporate governance committee is a small group of a company’s board members tasked with choosing and evaluating directors and setting the rules that guide how the board operates. Think of it as the board’s hiring and rule-making team: it shapes leadership, board makeup, independence and ethical standards, which in turn influence how well the company is overseen and how investor interests are protected.

continuous service financial

"provided that the Reporting Person provides continuous service as a member"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aldeyra Therapeutics (ALDX) disclose on this Form 4?

Aldeyra Therapeutics disclosed stock option grants to director William D. Clark. He received two option awards over common stock, reported as derivative acquisitions rather than open-market purchases, reflecting equity-based director compensation instead of cash transactions.

How many stock options did Aldeyra director William D. Clark receive?

Clark received two stock option grants: one covering 2,323 shares and another covering 70,000 shares of Aldeyra common stock. Both positions are reported as newly awarded derivative securities held directly following the transactions.

What is the exercise price of William D. Clark’s Aldeyra stock options?

Both option awards have an exercise price of $1.72 per share. This means Clark can buy Aldeyra common stock at $1.72 if and when the options vest and he chooses to exercise them before they expire.

When do William D. Clark’s Aldeyra stock options expire?

The Form 4 shows an expiration date of June 8, 2036 for each stock option grant. Clark generally must exercise any vested options on or before that date to acquire the underlying Aldeyra common shares.

What are the vesting conditions for Aldeyra director William D. Clark’s options?

Each option becomes exercisable for 100% of its shares after one year, provided Clark continues serving. One grant requires continuous service on the Board of Directors, and the other requires continuous service on the Nominating/Corporate Governance Committee through the vesting date.

Are William D. Clark’s Aldeyra option grants open-market purchases or compensation awards?

These transactions are reported with code A as a grant or award acquisition. They represent equity compensation rather than open-market buying, with no purchase price paid at grant beyond the stated future exercise price of $1.72 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark William D

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.72	06/09/2026		A		70,000		(1)	06/08/2036	Common Stock	70,000	$0	70,000	D
Stock Option (Right to Buy)	$1.72	06/09/2026		A		2,323		(2)	06/08/2036	Common Stock	2,323	$0	2,323	D

Explanation of Responses:

1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.

2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.

	/s/ William D Clark	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)